Tyson Foods, Inc. vs GeneDx Holdings Corp — how do they compare? Tyson Foods, Inc. trades at $56.59 (market cap $19.85B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Tyson Foods, Inc. is far larger — about 8.1× GeneDx Holdings Corp's market cap, and Tyson Foods, Inc. pays a 3.62% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TSN | WGS | |
|---|---|---|
Market Cap | $19.85B | $2.44B |
Sector | Consumer Staples | Technology |
52-Week High | $68.75 | $167.51 |
52-Week Low | $50.72 | $34.51 |
Enterprise Value | $27.12B | $2.48B |
Dividend Yield | 3.62% | — |
Signals from Pluang's Aura AI — not financial advice
Tyson Foods (TSN) trades at $55.97, down 2.08% on the day, amid a bearish technical signal and mixed quarterly performance. Recent Q3 2026 earnings of $0.99 per share beat estimates, but revenue and volumes declined year-over-year. The company maintains a strong cash flow from operations of $2.16B in 2025, though net income margins are thin at 1.03%. Analyst consensus is a Buy with a $68.50 price target, highlighting a potential 22% upside from current levels.
The outlook for TSN is cautiously optimistic, with valuation metrics like P/S of 0.36 and EV/EBITDA of 10.38 suggesting potential undervaluation. Key risks include persistent losses in the beef segment due to high cattle costs and competitive pressures. Investment opportunity lies in the strength of chicken and prepared foods divisions, supported by a stable dividend yield. Monitoring Q3 2026 earnings release and beef margin normalization is critical for future performance.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Trailing returns across standard periods
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →